Rathbones Group’s Rocket Pharmaceuticals RCKT Stock Holding History

Rathbones Group’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20,000	Closed	-$70.2K	–	665
2025 Q4	$70.2K	Hold	20,000	–	–	﹤0.01%	614
2025 Q3	$65.2K	Hold	20,000	–	–	﹤0.01%	620
2025 Q2	$49K	Sell	20,000 -10,000	-33%	-$50.7K	﹤0.01%	604
2025 Q1	$200K	Hold	30,000	–	–	﹤0.01%	531
2024 Q4	$377K	Hold	30,000	–	–	﹤0.01%	450
2024 Q3	$554K	Hold	30,000	–	–	﹤0.01%	403
2024 Q2	$646K	Hold	30,000	–	–	﹤0.01%	375
2024 Q1	$808K	Hold	30,000	–	–	﹤0.01%	349
2023 Q4	$899K	Hold	30,000	–	–	0.01%	329
2023 Q3	$615K	Buy	+30,000	New	+$545K	﹤0.01%	367
2021 Q3	–	Sell	-5,000	Closed	-$221K	–	434
2021 Q2	$221K	Hold	5,000	–	–	﹤0.01%	391
2021 Q1	$222K	Hold	5,000	–	–	﹤0.01%	369
2020 Q4	$274K	Buy	+5,000	New	+$182K	﹤0.01%	338
2018 Q1	–	Sell	-2,500	Closed	-$26K	–	327
2017 Q4	$26K	Hold	2,500	–	–	﹤0.01%	314
2017 Q3	$18K	Hold	2,500	–	–	﹤0.01%	317
2017 Q2	$19K	Hold	2,500	–	–	﹤0.01%	316
2017 Q1	$20K	Hold	2,500	–	–	﹤0.01%	322
2016 Q4	$61K	Hold	2,500	–	–	﹤0.01%	305
2016 Q3	$95K	Buy	+2,500	New	+$78.6K	﹤0.01%	297

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Rathbones Group's RCKT Position: Q1 2026 in Review

Rathbones Group sold out of Rocket Pharmaceuticals (RCKT) in Q1 2026, closing a stake of 20,000 shares — an estimated $70.2K sold.

Rathbones Group first reported a position in RCKT in Q3 2016 and held it in 19 quarters. The position peaked at $899K in Q4 2023. 199 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.

Rathbones Group reported no remaining Rocket Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Rathbones Group sold 20,000 Rocket Pharmaceuticals shares in Q1 2026, an estimated $70.2K.
Rathbones Group first reported a position in Rocket Pharmaceuticals in Q3 2016 and held it in 19 quarters.
Rathbones Group's Rocket Pharmaceuticals position peaked at $899K in Q4 2023.
199 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.

Based on Rathbones Group's 13F filing for Q1 2026, filed 12 May 2026.